Prime Medicine, Inc.
PRME
$0.11
Change (1 day)
$9.80
Year High
$2.56
Year Low
Categories
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Prime Medicine, Inc. (PRME) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -27,941,000 | 60.78 M | 193.85 M | 142.98 M | |
| 2022 | -158,875,000 | 360.31 M | 360.31 M | 293.92 M | |
| 2021 | -175,014,000 | 62.3 M | 301.86 M | 270.58 M | |
| 2020 | -36,957,485 | 21.31 M | 54.78 M | 53.4 M | |
| 2019 | -8,647,000 | 7.31 M | 8.7 M | 8.7 M |